Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial

Open access

Abstract

BACKGROUND Idiopathic pulmonary fibrosis is a fatal disease for which no effective treatment exists. We assessed whether treatment with interferon gamma-1b improved survival compared with placebo in patients with idiopathic pulmonary fibrosis and mild-to-moderate impairment of pulmonary function. METHODS 826 patients with idiopathic pulmonary fibrosis were enrolled from 81 centres in seven European countries, the USA, and Canada. Patients were randomly assigned (double-blind) in a 2:1 ratio to receive 200 microg interferon gamma-1b (n=551) or equivalent placebo (n=275) subcutaneously, three times per week. Eligible patients were aged 40-79 years, had been diagnosed in the past 48 months, had a forced vital capacity of 55-90% of the predicted value, and a haemoglobin-corrected carbon monoxide diffusing capacity of 35-90% of the predicted value. The primary endpoint was overall survival time from randomisation measured at the second interim analysis, when the proportion of deaths had reached 75% of those expected by the study conclusion. This study is registered with ClinicalTrials.gov, number NCT00075998. FINDINGS At the second interim analysis, the hazard ratio for mortality in patients on interferon gamma-1b showed absence of minimum benefit compared with placebo (1.15, 95% CI 0.77-1.71, p=0.497), and indicated that the study should be stopped. After a median duration of 64 weeks (IQR 41-84) on treatment, 80 (15%) patients on interferon gamma-1b and 35 (13%) on placebo had d…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(09)60551-1

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Research works printed but not linked: 2

  1. Ziesche, 2002, Long term survival in idiopathic pulmonary fibrosis patients treated with interferon gamma-1b, Chest, 122, S207
  2. Selman, 2003, A dark side of interferon-γ in the treatment of idiopathic pulmonary fibrosis?, Am J Respir Crit Care Med, 167, 945

Cited by

See all 547

Metadata

Authors
King, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., Valeyre, D., & du Bois, R. M.
Affiliations
  • University of California, San Francisco (US)
  • University of Turin (IT)
  • Ruhrlandklinik (DE)
  • Vanderbilt University Medical Center (US)
  • Duke University (US)
  • Medical University of South Carolina (US)
  • Universitair Ziekenhuis Leuven (BE)
  • Assistance Publique – Hôpitaux de Paris (FR)
Corresponding author
King, Talmadge E
Venue
The Lancet
Publisher
Elsevier BV
Published
2009-07
Volume
374
Issue
9685
Pages
222-228
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2131029325
Cited by
531
References
23
Citations by year
2026: 9 · 2025: 16 · 2024: 23 · 2023: 20 · 2022: 26 · 2021: 32 · 2020: 15 · 2019: 26 · 2018: 21 · 2017: 36 · 2016: 38 · 2015: 41 · 2014: 39 · 2013: 44 · 2012: 49
FWCI
40.54
Type
journal article
Language
en
Open access
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion, cc-by-nc-nd)
  • Document Server@UHasselt (UHasselt) (submittedVersion, other-oa)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
  • Use Siena air (University of Siena) (submittedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion)
Funders
University of California, San Diego
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords
idiopathic pulmonary fibrosis, interferon gamma-1b, survival, mortality, treatment efficacy, adverse events, influenza-like illness, medication adherence, lung function, diffusing capacity for carbon monoxide, forced vital capacity, subcutaneous interferon therapy, INSPIRE trial, subgroup analysis bias, treatment effect heterogeneity
MeSH terms
Aged, Analysis of Variance, Double-Blind Method, Drug Administration Schedule, Europe, Exercise Test, Female, Humans, Injections, Subcutaneous, Interferon-gamma, Male, North America, Pulmonary Diffusing Capacity, Recombinant Proteins, Severity of Illness Index, Vital Capacity, Survival Rate, Proportional Hazards Models, Treatment Failure, Disease Progression, Kaplan-Meier Estimate, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(09)60551-1
The paper
King, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., Valeyre, D., & du Bois, R. M. (2009). Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(09)60551-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.